Background In the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), the composite primary endpoint of stroke, myocardial infarction, or death during the periprocedural period or ipsilateral stroke thereafter did not diff er between carotid artery stenting and carotid endarterectomy for symptomatic or asymptomatic carotid stenosis. A secondary aim of this randomised trial was to compare the composite endpoint of restenosis or occlusion.
Introduction
In the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), 1 no diff erence was reported between carotid artery stenting and carotid endarterectomy for the composite primary endpoint of stroke, myocardial infarction, or death during the periprocedural period or ipsilateral stroke thereafter. The secondary analysis of the individual components of the primary endpoint established that stroke occurred more frequently after carotid artery stenting, as did myocardial infarction after carotid endarterectomy. 1 That the frequency of the composite endpoint did not diff er between carotid artery stenting and carotid endarterectomy underscores the need for a comparison of the anatomic durability of these revascularisation procedures. Many participants in CREST were asymptomatic, so the long-term durability of revascularisation becomes even more important.
The occurrence of restenosis after carotid artery stenting [2] [3] [4] [5] and carotid endarterectomy [6] [7] [8] ranges from 5% to 20%, depending on its defi nition and the duration of follow-up. Restenosis at 6 and 12 months were prespecifi ed secondary endpoints in CREST. Before review of ultrasound data, the CREST investigators agreed that analysis at 24 months would be more informative and so decided that restenosis at 24 months would be the primary focus of this analysis. Hence, we report the 2-year anatomic durability of carotid artery stenting and carotid endarterectomy. We also identify factors aff ecting risk of restenosis and compare frequency of stroke and repeat revascularisation between the treatment groups.
Methods

Study design and participants
The study design and the primary results of CREST have been reported previously.
enrolled at 117 clinical centres in the USA and Canada between Dec 21, 2000, and July 18, 2008. Patients who had had a transient ischaemic attack, amaurosis fugax, or a minor non-disabling stroke involving the study carotid artery within 180 days before randomisation were eligible if they had stenosis of 50% or more by angiography, 70% or more by ultrasonography, or 70% or more by computed tomo graphy angiography or magnetic resonance angiography when the stenosis by ultrasonography was 50-69%. Patients who were asymptomatic were eligible when they had stenosis of 60% or more by angiography, 70% or more by ultra sonography, or 80% or more by computed tomo graphy angiography or magnetic resonance angiography when the stenosis on ultrasonography was 50-69%. The full eligibility criteria have been reported elsewhere. 1, 9, 10 The protocol was approved by the ethics committees of all study institutions and administrative sites. Written informed consent was obtained from all participants before their revascularisation procedure.
Randomisation and masking
Patients were randomly assigned to either carotid artery stenting or carotid endarterectomy through a web-based system with a permuted block design (random block sizes of two, four, or six), and were stratifi ed according to centre and symptomatic status. Randomisation occurred after the patient and treating physician could arrange for revascularisation to be done within 2 weeks. Stroke and myo cardial infarction were adjudicated by specialty committees masked to treatment assignment. All other out comes were assessed by investigators unmasked to treat ment allocation. Investigators and patients were unmasked.
Procedures
Carotid endarterectomy was undertaken according to well established techniques (standard or eversion endarterectomy) on the basis of the individual preferences of 477 surgeons. Carotid artery stenting was undertaken with a prespecifi ed self-expanding nitinol stent and an embolic protection device (RX Acculink and RX Accunet, Abbott Vascular, Santa Clara, CA, USA). 224 participating interventionists were selected after successful comple tion of a mandatory non-randomised lead-in creden tialling phase of carotid artery stenting procedures. 10, 11 Full details of these procedures are provided elsewhere. 1, 9, 10 To maintain consistency in the follow-up timepoints, patients who underwent their assigned revascularisation procedure within 30 days of randomisation and who had at least one follow-up ultrasound within 24 months were included in this secondary analysis. Additionally, we focused on patients who received their assigned treatment, because we were interested in restenosis rates specifi cally associated with carotid artery stenting and carotid endarterectomy (and not the intention to be treated by these procedures). Those who did not receive any treatment did not establish a condition of no stenosis that would have meant subsequent restenosis could occur.
Duplex ultrasonography was done at baseline and 1, 6, 12, 24, and 48 months after revascularisation. Duplex ultrasonography 12 was under taken at CREST-certifi ed 12 clinical centre vascular la boratories with a standardised protocol that stipulated 16 doppler waveform samples at every examination (eight samples were taken from each side of the neck: six at 1-2 cm intervals along the common and internal carotid arteries, one from the external carotid artery, and one from the vertebral artery). Waveform samples were to be obtained at a 60-degree angle between the ultrasound beam and the long axis of the vessel. The highest systolic velocity measurement from each treated carotid pathway was used to identify restenosis. Ultrasound laboratories use diff erent methods and velocity measurements are angle-dependent. 13 Accordingly, ultrasound images and doppler waveforms were forwarded to the Ultrasound Core Laboratory at the University of Washington Ultrasound Reading Center (URC) for uniform assessment and coding. Clinical centres submitted ultrasound data primarily in digital form. A few centres submitted paper prints that were scanned and digitised at the URC. The velocity values submitted were entered into the URC database.
Images and waveforms were read by a registered sonographer certifi ed by the American Registry of Diagnostic Medical Sonographers and trained by the URC. The reader confi rmed images, values, and alignment of the ultrasound-beam cursor with the vessel axis on the B-mode image; image and waveform readings were then reviewed by a senior sonographer or the URC Director (KWB). Both reader and reviewer verifi ed the selection, location, labelling of every image and waveform pair, and cursor alignment. When the cursor was misaligned, the doppler examination angle was measured again and the angle-adjusted velocity was recalculated. The equation for recalculation was: new velocity=old velocity × cos(old angle)/cos(new angle).
Corrections and changes marked in the reader and reviewer process were entered into the database and used to update the information. When the reviewer disagreed with the reader, the case was returned to the reader for confi rmation. When the disagreement was not resolved, an adjudicator rendered a fi nal decision and presented the case to the readers and reviewers to minimise future interpretation diff erences. The fi nal adjudicated angleadjusted velocity value and verifi ed duplex ultra sonography was reported by the URC and these values were used in our analysis.
The main endpoint in this secondary analysis was a composite of restenosis, defi ned as 70% or more diameter-reducing stenosis, or target-artery occlusion occurring at the ultrasound scans at 1, 6, 12, or 24 months.
The 70% threshold to defi ne high-grade restenosis is the most accepted threshold and has been used in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS), 3 the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial, 4 and the Endarterectomy versus Angioplasty in Patients with Severe Symptomatic Carotid Stenosis (EVA-3S) trial. 5 Assessment of restenosis was done when the peak systolic velocity at any location within the treated internal or common carotid artery reached or exceeded 3·0 m/s. Analysis of the frequency of high-grade restenosis and occlusion was a prespecifi ed secondary analysis of the CREST protocol. The decision to use 3·0 m/s as the defi nition for restenosis was also made before un blinding of the restenosis data. Several single-institution reports [14] [15] [16] [17] [18] support the use of 3·0 m/s or more as an appropriate threshold to identify high-grade restenosis.
Target-artery occlusion was established on duplex ultrasonography when no fl ow signal was detected at any location within the treated internal or common carotid artery. Included in this category were arteries with near occlusion defi ned by a diastolic velocity of zero, low systolic velocity at some locations, or an inability to fi nd doppler signals at some locations within the treated arterial segments. Residual stenosis immediately after re vascularisation was measured only in the group undergoing carotid artery stenting and was therefore not compared with carotid endarterectomy. The frequency with which ipsilateral stroke occurred in the period after procedures had been completed and the frequency of repeat surgical revascularisation, balloon angioplasty, or repeat carotid artery stenting done on target arteries were also assessed.
Concerns have been raised that ultrasound velocity criteria designed for native carotid arteries could overestimate stenosis in the presence of a stent, 14, 19 because the reduced compliance of the vessel wall could increase the peak systolic velocity. 19 Therefore, use of an appropriate velocity threshold is central to the comparison of restenosis after carotid endarterectomy and carotid artery stenting. We have used the threshold of 3·0 m/s to investigate the primary endpoint, acknowledging that it is not universally accepted. To address potential threshold-dependent variations in restenosis determination, we undertook an exploratory analysis in which diff erent thresholds (greater or less than 3·0 m/s) were applied to the data. Restenosis rates thus obtained for carotid artery stenting and carotid endarterectomy were compared.
Statistical analysis
The frequency of restenosis was calculated by KaplanMeier survival estimates and was compared during a 2-year follow-up period between patients undergoing carotid artery stenting and carotid endarterectomy. In analyses specifi ed after the initial analysis plan but before the data were reviewed, we used proportional hazards analyses to assess the univariate association between baseline clinical charac teristics and the risk of the composite endpoint in the combined cohort and for carotid artery stenting and carotid endarterectomy separately to identify potential diff erences in risk factors as defi ned at the time of randomisation. Backwards stepwise procedures were used to establish the most parsimonious model for the combined cohort. We tested the clinical characteristics diabetes, dyslipidaemia, hypertension, smoking, pre vious cardiovascular disease or coronary artery bypass grafting, pretreatment stenosis category, age, symptomatic status, ethnic origin, sex, time to treatment after randomisation, and antiplatelet treatment. The number of strokes that occurred in the 2 years after the procedures was compared by treatment group in the patients with and without the composite endpoint. Additionally, we compared the proportion of patients undergoing repeat revascularisation. Analyses were done with SAS (version 9.2).
CREST is registered with ClinicalTrials.gov, number NCT00004732.
Role of the funding source
Representatives of the study sponsors were involved in the review of the report and the study design, but were not directly involved in data collection, data management, data analysis, data interpretation, writing of the report, or the decision to submit for publication. The corresponding author had full access to the data for this study and had fi nal responsibility for the decision to submit for publication.
Results
Of the 1262 patients randomly assigned to carotid artery stenting who had data included in the main CREST analysis, 1136 received their allocated treatment and 1123 did so within 30 days of randomisation. Of the 1240 patients randomly assigned to carotid endarterectomy who had data included in the main CREST analysis, 1184 received their assigned treatment and 1151 did so within 30 days of randomisation. Reasons for patients not receiving their assigned treatment have been reported previously.
1 Within our cohort, 37 patients who underwent carotid artery stenting and 46 who underwent carotid endarter ectomy did not have carotid duplex ultra sonography during follow-up data supplied to the Ultrasound Core Laboratory. Therefore, 2191 patients received their as signed treatment within 30 days of randomisation and had ultrasonography reviewed at the Ultrasound Core Laboratory, and form the analytic cohort for this report (1086 undergoing carotid artery stenting, 1105 under going carotid endarterectomy). Table 1 shows baseline clinical characteristics. Patients excluded from this secondary analysis were older, less likely to be white or dyslipidaemic, and more likely to be female and have hypertension than were those who were included (table 1) . Demographic charac teristics, symptomatic status, and risk-factor distribution did not diff er between those who had carotid artery stenting versus those having carotid endarterectomy (table 1) . However, patients who underwent carotid endarterectomy had their procedures slightly later than did those receiving carotid artery stenting, and more patients undergoing carotid artery stenting received antiplatelet treatment than did those assigned to carotid endarterectomy ( [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] in both groups). The proportion of cases in which reanalysis of the images or discussion about the results occurred was small: reanalysis was necessary in 3·1% of patients at baseline, 2·9% at 1 month, 2·2% at 6 months, 3·0% at 12 months, and 1·6% at 24 months.
The composite outcome of restenosis or occlusion occurred in 120 patients (58 carotid artery stenting, 62 carotid endarterectomy). The Kaplan-Meier estimate for the frequency of the composite outcome in 2 years was 6·0% for carotid artery stenting and 6·3% for carotid endarterectomy (hazard ratio [HR] 0·90, 95% CI Patients with the composite outcome were more likely to be younger, women, hypertensive, diabetic, and dyslipidaemic than were those who did not reach the outcome (table 2) . Backwards stepwise analysis indicated female sex, diabetes, and dyslipidaemia were related to restenosis ( Excluding 96 patients who had a periprocedural event, participants who had restenosis or occlusion within 2 years were at greater risk for ipsilateral stroke after the periprocedural period up to the end of follow-up than were those who did not have restenosis (HR 4·37, 95% CI 1·91-10·03; p=0·0005, adjusted for age, sex, and symptomatic status). Six of 56 patients who had undergone carotid endarterectomy and had restenosis and one of 55 who had undergone carotid artery stenting had strokes after the periprocedural period. Of 1984 patients who did not have restenosis or a periprocedural event, ipsilateral strokes occurred in 30 (12 in the carotid endarterectomy group, 18 in the carotid artery stenting group).
Patients who developed restenosis were more likely to be women, hypertensive, diabetic, and dyslipidaemic than were those who did not develop restenosis, irrespective of In the exploratory analysis, diff erent thresholds of peak systolic volume yielded variable frequencies of the composite endpoint (fi gure 2). However, the frequencies diff ered by treatment received only for the 2·1 m/s threshold (log rank p=0·02; fi gure 2).
Discussion
Our results provide three key fi ndings. First, carotid artery stenting and carotid endarterectomy are associated with similar frequencies of restenosis in patients with symptomatic or asymptomatic carotid stenosis. Second, female sex, diabetes, and dyslipidaemia are independent predictors of restenosis after carotid artery stenting and carotid endarterectomy, but smoking was associated with an increased likelihood of restenosis after carotid endarterectomy. Finally, restenosis is associated with an increased risk of ipsilateral stroke after both procedures.
We have analysed 2-year follow-up data for 2191 conventional-risk patients, of whom almost half were asymptomatic. Our study is the most comprehensive investigation of restenosis after carotid revascularisation (panel). Patients were given available pharmacological, surgical, and endovascular treatments. The results are therefore readily applicable to clinical
Panel: Research in context
Systematic review
We searched PubMed for reports published in English between Jan 1, 1990, and April 30, 2012, with the terms "clinical trials", "carotid endarterectomy", "carotid stenting", "restenosis", and "recurrent stenosis". References within these reports were also checked for additional related citations. We manually reviewed the reports and identifi ed those of multicentre randomised trials with available information about enrolment and outcomes during follow-up. We identifi ed four trials of restenosis in patients who had undergone carotid artery stenting or carotid endarterectomy. [3] [4] [5] 20 We noted that published trials have varying conclusions (table 4): they have shown no diff erence in restenosis, an increase in frequency after endarterectomy, or an increase in frequency after stenting. However, bare-metal stenting in the coronary artery is known to be associated with increased rates of recurrent stenosis.
21
Interpretation
On the basis of the results from the previous trials, [3] [4] [5] 20 we did this secondary analysis of CREST with the hypothesis that carotid artery stenting would result in a higher rate of restenosis than would carotid endarterectomy. The large number of patients included in our study-many of whom were asymptomatic-means that it is the most comprehensive analysis of restenosis after carotid revascularisation. We have shown that the procedures are associated with similar rates of restenosis. Our results provide reassurance that carotid revascularisation is durable, and identify subsets of patients that might benefi t from close surveillance for recurrence. 
Previous cardiovascular disease or coronary artery bypass graft
Pretreatment stenosis of at least 70% 1·68 (0·67-4·19) 0·89 (0·45-1·74) 0·2725
Treatment within 7 days of randomisation 0·79 (0·47-1·33) 0·67 (0·41-1·10) 0·6475
Antiplatelet treatment 1·94 (0·27-14·04) 0·78 (0·34-1·81) 0·4059
The interaction analysis indicates a risk factor or risk factors that were associated with restenosis after one but not the other revascularisation procedure. *p values refer to the presence or absence of a signifi cant interaction between type of revascularisation procedure and risk factor for the outcome of restenosis. 4 and the EVA-3S trial (n=507) 5 also included only symptomatic patients (table 4) .
Carotid artery revascularisation is a durable procedure. 2-year frequencies of our composite endpoint after carotid artery stenting and carotid endarterectomy provide a guide with which to compare future studies. Although our initial estimates to 4 years showed similar frequencies to those for 2 years, we prefer to focus on the 2-year values because the number of patients who had been followed to 48 months was small and so these estimates could be inaccurate. Initial concerns had been expressed regarding exaggerated neointimal hyperplasia after carotid artery stenting on the basis of experience with coronary 21 and intracranial arterial 25 bare-metal stenting. These concerns were not substantiated in CREST. Low restenosis rates after carotid stenting have also been reported in small singleinstitution studies and ran domised trials (table 4) .
We noted no diff erence in 2-year frequency of restenosis between the groups after adjusting for age, sex, and symptomatic status. However, the SPACE trial 4 showed that restenosis occurred more frequently in 2 years after carotid artery stenting than after carotid endarterectomy (11·1% vs 4·6% of patients; p=0·0007). The CREST results off er the highest reliability and uniformity of comparison, because ultrasonography was read centrally with uniform and updated velocity criteria for the endpoint. 12 In SAPPHIRE, 20 re intervention was used as a surrogate for restenosis, with the assumption that the reinterventions were all done at the assigned threshold of a diameter reduction of 80% or more. In SPACE, 4 restenosis interpretations reported from individual clinical centres were used. In EVA-3S, 5 most ultrasound tests were done outside the participating centres, and an unspecifi ed number of outcomes were based on written reports from clinical centres. Frequency of restenosis after 2 years remains unknown because previous studies have shown that restenosis can be reported 2 years after carotid artery stenting or carotid endarterectomy. Accordingly, the CREST cohort is being followed up to 10 years with annual ultrasonography.
The defi nition of restenosis in CREST was based on the criteria used in previously published trials. 4, 5, 20 Although restenosis has sometimes been defi ned as any diameter reduction of at least 50%, the clinical relevance of this defi nition is not established, and we did not seek to identify this subset of patients. Duplex ultrasound velocity thresholds to derive estimates of stenosis in native carotid arteries are well established and validated. 26, 27 The CREST defi nition of 3 m/s or more was based on a comparison of more than 500 duplex ultrasound and anatomical comparative imaging studies. The SPACE investigators used a lower peak systolic velocity threshold 4 -2·1 m/s-which could explain why the frequency of restenosis was higher than in EVA-3S, 5 in which a threshold of 3·0 m/s was used. As the threshold was reduced in our exploratory analysis, the frequency of restenosis increased more in patients who had undergone carotid Previous trials have identifi ed risk factors for restenosis on the basis of assessments of patients after carotid artery stenting and carotid endarterectomy as a combined group. In CREST, patients with restenosis were most likely to be women with diabetes and dyslipidaemia. No previous randomised trial has identifi ed an increased likelihood for women to develop restenosis after carotid revascularisation. Previous single-institution studies of carotid artery stenting 28 and larger studies of coronary and intracranial arteries 25 have implied that diabetes is a risk factor for recurrent stenosis after carotid stenting. This association has not been identifi ed in other trials of carotid artery stenting or carotid endarterectomy. The SAPPHIRE 20 and SPACE 4 trials did not include assessments of risk factors. Smoking in the CAVATAS trial 3 and increasing age in EVA-3S 5 were shown to predict restenosis. The injury patterns and biological eff ects of the two procedures are probably diff erent. They could be aff ected diff erently by clinical characteristics of patients. We showed that the risk factors for restenosis were generally similar for carotid artery stenting and for carotid endarterectomy, but that smoking diff ered with procedure. A variable eff ect of risk factors on restenosis after carotid artery stenting compared with carotid endarterectomy has not been identifi ed previously.
Our results indicate that restenosis was associated with an increased risk of ipsilateral stroke after carotid artery stenting or carotid endarterectomy. Occurrence of both stroke and restenosis was identifi ed at the time of an assigned follow-up. Therefore, we cannot state with certainty whether restenosis developed before or after stroke. Furthermore, restenosis is cumulative and results from progressive accumulation of neointimal or atherosclerotic material. On the basis of our protocol, we can clearly defi ne the time of diagnosis of restenosis and not the time of development of restenosis. A limitation of the study is that the results do not allow inference about the potential need for repeat carotid artery stenting or carotid endarterectomy to address the increased risk of stroke. Repeat revascularisation for restenosis was infrequent. Because the threshold restenosis at which these procedures were undertaken was not protocol-driven in CREST, some patients received reintervention without an established diagnosis of high-grade stenosis from the Ultrasound Core Laboratory. The method of revascularisation was not protocol-driven and ranged from repeat endarterectomy to balloon angioplasty or repeat stenting.
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